治疗遗传病的RNA药物研究进展

RNA therapeutics inhibit the expression of specific proteins/RNAs by targeting complementary sequences of corresponding genes, or synthesize proteins encoded by the desired genes to treat genetic diseases. RNA-based therapeutics are categorized as oligonucleotide drugs (antisense oligonucleotides, small interfering RNA, RNA aptamers), and mRNA drugs. The antisense oligonucleotides and small interfering RNA for treatment of genetic diseases have been approved by the FDA in the United State, while RNA aptamers and mRNA drugs are still in clinical trials. Chemical modifications are applied to RNA drugs, such as pseudouridine modification of mRNA, to reduce immunogenicity and improve the efficacy. The secure and effective delivery systems like lipid-based nanoparticles, extracellular vesicles, and virus-like particles are under development to address stability, specificity, and safety issues of RNA drugs. This article provides an overview of the specific molecular mechanisms of 11 RNA drugs currently used for treating genetic diseases, and discusses the research progress of chemical modifications and delivery systems of RNA drugs.

[1]  A. Kaye,et al.  Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis. , 2023, Health psychology research.

[2]  K. Witwer,et al.  Extracellular vesicles: the next generation in gene therapy delivery. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  M. Somers.  Primary Hyperoxaluria: A Need for New Perspectives in an Era of New Therapies. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  A. González-Duarte,et al.  Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[5]  Hongchuan Jin,et al.  RNA-based therapeutics: an overview and prospectus , 2022, Cell Death & Disease.

[6]  J. Manautou,et al.  Casimersen for the treatment of Duchenne muscular dystrophy. , 2022, Trends in pharmacological sciences.

[7]  J. Conde,et al.  Nanodelivery of nucleic acids , 2022, Nature Reviews Methods Primers.

[8]  Jiancheng Wang,et al.  Non-viral vectors for RNA delivery , 2022, Journal of Controlled Release.

[9]  James E. Dahlman,et al.  Drug delivery systems for RNA therapeutics , 2022, Nature Reviews Genetics.

[10]  J. Chao,et al.  Extracellular vesicle‐mediated delivery of circDYM alleviates CUS‐induced depressive‐like behaviours , 2022, Journal of extracellular vesicles.

[11]  Jeonghwan Kim,et al.  Chemistry of Lipid Nanoparticles for RNA Delivery. , 2021, Accounts of chemical research.

[12]  D. Peer,et al.  RNA delivery with a human virus-like particle , 2021, Nature Biotechnology.

[13]  L. Pyle,et al.  Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. , 2021, The New England journal of medicine.

[14]  Magdalena M. Zak,et al.  Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery , 2021, Pharmaceutics.

[15]  E. Koonin,et al.  Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery , 2021, Science.

[16]  E. J. Chung,et al.  Strategies to deliver RNA by nanoparticles for therapeutic potential. , 2021, Molecular aspects of medicine.

[17]  S. B. Singh,et al.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders , 2021, Cellular and Molecular Neurobiology.

[18]  Yahiya Y. Syed.  Givosiran: A Review in Acute Hepatic Porphyria , 2021, Drugs.

[19]  J. Lieske,et al.  Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. , 2021, The New England journal of medicine.

[20]  S. D. De Smedt,et al.  The dawn of mRNA vaccines: The COVID-19 case , 2021, Journal of Controlled Release.

[21]  S. Crooke,et al.  Antisense technology: an overview and prospectus , 2021, Nature Reviews Drug Discovery.

[22]  K. Wagner,et al.  Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments , 2021, Cells.

[23]  J. Manautou,et al.  The growth of siRNA-based therapeutics: updated clinical studies. , 2021, Biochemical pharmacology.

[24]  A. Marson,et al.  Genetic Disease and Therapy. , 2021, Annual review of pathology.

[25]  R. Finkel,et al.  Nusinersen Treatment in Adults With Spinal Muscular Atrophy , 2021, Neurology. Clinical practice.

[26]  Xiaodong Sun,et al.  Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice , 2021, Nature Biomedical Engineering.

[27]  S. Servidei,et al.  Patisiran in hereditary transthyretin-mediated amyloidosis , 2020, The Lancet Neurology.

[28]  Takashi Nakamura,et al.  Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine , 2020, Journal of Controlled Release.

[29]  James E. Dahlman,et al.  Treating cystic fibrosis with mRNA and CRISPR. , 2020, Human gene therapy.

[30]  R. Langer,et al.  Advances in oligonucleotide drug delivery , 2020, Nature Reviews Drug Discovery.

[31]  S. Anwar,et al.  Golodirsen for Duchenne muscular dystrophy. , 2020, Drugs of today.

[32]  A. Sahebkar,et al.  CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review. , 2020, Current Pharmaceutical Biotechnology.

[33]  L. Laurent,et al.  RNA delivery by extracellular vesicles in mammalian cells and its applications , 2020, Nature Reviews Molecular Cell Biology.

[34]  Mark I. McCarthy,et al.  A brief history of human disease genetics , 2020, Nature.

[35]  K. Anderson.  Acute hepatic porphyrias: Current diagnosis & management. , 2019, Molecular genetics and metabolism.

[36]  M. Ávila,et al.  Messenger RNA therapy for rare genetic metabolic diseases , 2019, Gut.

[37]  A. Goldberg,et al.  Mipomersen and its use in familial hypercholesterolemia , 2018, Expert opinion on pharmacotherapy.

[38]  Yuan Zhang,et al.  CircDYM ameliorates depressive-like behavior by targeting miR-9 to regulate microglial activation via HSP90 ubiquitination , 2018, Molecular Psychiatry.

[39]  S. Dowdy,et al.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. , 2018, Nucleic acid therapeutics.

[40]  Nicole M. Gaudelli,et al.  Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage , 2017, Nature.

[41]  Adriane N. Irwin,et al.  Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns—an Alternative Viewpoint , 2017, Pharmacotherapy.

[42]  Daniel G. Anderson,et al.  Advances in the delivery of RNA therapeutics: from concept to clinical reality , 2017, Genome Medicine.

[43]  S. Nelson,et al.  FDA Approval of Eteplirsen for Muscular Dystrophy. , 2017, JAMA.

[44]  J. Sackner-Bernstein.  FDA Approval of Eteplirsen for Muscular Dystrophy. , 2017, JAMA.

[45]  B. Sullenger,et al.  From the RNA world to the clinic , 2016, Science.

[46]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[47]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[48]  A. Schambach,et al.  Gene therapy on the move , 2013, EMBO molecular medicine.

[49]  John J Rossi,et al.  RNAi and small interfering RNAs in human disease therapeutic applications. , 2010, Trends in biotechnology.

[50]  I. MacRae,et al.  The RNA-induced Silencing Complex: A Versatile Gene-silencing Machine* , 2009, The Journal of Biological Chemistry.

[51]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[52]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[53]  C. Wu,et al.  Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. , 1996, Human molecular genetics.

[54]  J. Marini,et al.  Ribozymes: structure, function, and potential therapy for dominant genetic disorders. , 1996, Annals of medicine.

[55]  T. Yokota,et al.  Viltolarsen: From Preclinical Studies to FDA Approval. , 2023, Methods in molecular biology.

[56]  M. Parodi,et al.  Pegaptanib : choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events , 2018 .

[57]  G. Baskerville.  Human gene therapy: application, ethics and regulation. , 1992 .